A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel
NCT06940739
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
RECRUITING
Status
42
Enrollment
INDUSTRY
Sponsor class
Conditions
Unresectable Melanoma
Metastatic Melanoma
Ocular Melanoma
Interventions
BIOLOGICAL:
IOV-3001
Sponsor
Iovance Biotherapeutics, Inc.